BiotechTube

Zonisamide + Carbamazepine

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Epilepsy

Conditions

Epilepsy

Trial Timeline

May 1, 2007 → Jan 1, 2011

NCT ID
NCT00477295

About Zonisamide + Carbamazepine

Zonisamide + Carbamazepine is a phase 3 stage product being developed by Eisai for Epilepsy. The current trial status is completed. This product is registered under clinical trial identifier NCT00477295. Target conditions include Epilepsy.

What happened to similar drugs?

20 of 20 similar drugs in Epilepsy were approved

Approved (20) Terminated (6) Active (0)
✅ZonegranEisaiApproved
✅Perampanel + PlaceboEisaiApproved
✅perampanelEisaiApproved
✅Perampanel Oral TabletEisaiApproved
✅PerampanelEisaiApproved
✅zonisamide low dose group + zonisamide high dose groupEisaiApproved
✅Zonisamide at targeted daily doses of 100-500 mg/day + Placebo administered to match targeted daily doses of 100-500 mg/dayEisaiApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT00848549Phase 3Completed
NCT00477295Phase 3Completed
NCT01127256ApprovedCompleted

Competing Products

20 competing products in Epilepsy

See all competitors
ProductCompanyStageHype Score
perampanelEisaiPhase 2
35
LacosamideUCBPhase 3
40
Zonisamide + PlaceboEisaiPhase 3
32
ZonegranEisaiApproved
35
perampanel + perampanelEisaiPhase 1
29
Perampanel + PlaceboEisaiApproved
35
perampanelEisaiApproved
35
E2007 + PlaceboEisaiPhase 2
35
Placebo + RufinamideEisaiPhase 3
40
E2007 (perampanel) + PlaceboEisaiPhase 2
35
Perampanel Oral TabletEisaiApproved
43
perampanelEisaiPhase 3
40
PerampanelEisaiPre-clinical
26
PerampanelEisaiApproved
43
Perampanel and Microgynon-30 + Perampanel and Microgynon-30EisaiPhase 1
29
PerampanelEisaiPhase 2
35
Zonisamide + PlaceboEisaiPhase 3
40
zonisamide low dose group + zonisamide high dose groupEisaiApproved
43
E2007 + E2007 + PlaceboEisaiPhase 2
35
Zonisamide at targeted daily doses of 100-500 mg/day + Placebo administered to match targeted daily doses of 100-500 mg/dayEisaiApproved
35